Lensar is known for developing the Ally robotic cataract laser treatment system, alongside Streamline software technology and ...
Alcon and Lensar are walking away from a proposed acquisition deal following pushback from the Federal Trade Commission (FTC) ...
One medtech analyst raises concerns that Lensar's acquisition by Alcon is in trouble due to the company's recent priority ...
Alcon and Lensar terminate merger due to FTC challenges. Lensar retains a $10M deposit and focuses on Ally laser growth. More updates on March 31.
Lensar (Nasdaq:LNSR) announced today that it reached an agreement with Alcon (NYSE:ALC) to terminate their planned merger.
The Federal Trade Commission said the transaction had threatened to raise prices and stifle innovation for cataract laser eye surgery systems.
Laser-assisted cataract surgery failed to pass a cost-effectiveness test versus standard phacoemulsification cataract surgery (PCS), data from the randomized FEMCAT trial showed. Femtosecond ...
Femtosecond laser-assisted cataract surgery (FLACS) was approved in the United States in 2009. Since that time, various publications have compared conventional surgery with FLACS. Many studies have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results